	Application No.	Applicant(s)
Notice of Allowability		
	10/789,105 Examiner	ROBERTS ET AL. Art Unit
	·	
	Christina Borgeest	1649
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. X This communication is responsive to the amendment of 8 January 2007.		
2. The allowed claim(s) is/are 1-5 and 7.		
 3. Acknowledgment is made of a claim for foreign priority ur a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 	been received.	
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t	.84(c)) should be written on the drawi he header according to 37 CFR 1.121(ngs in the front (not the back) of d).
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
		*
•		•
•		
Attachment(s) 1. ☑ Notice of References Cited (PTO-892)	5. Notice of Informal F	Patent Application
Notice of References Cited (P10-092) Notice of Draftperson's Patent Drawing Review (PT0-948)	6. ☐ Interview Summary	, .
3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	Paper No./Mail Da	te
	7. X Examiner's Amenda	ment/Comment
4. Examiner's Comment Regarding Requirement for Deposit	8. X Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9. Other	
•		

Application/Control Number: 10/789,105

Art Unit: 1649

EXAMINER'S AMENDMENT

The application has been amended as follows: Withdrawn claims 8-17 are hereby cancelled. In response to the restriction requirement, Group I (claims 1-7) were elected without traverse, thus claims 8-17 were withdrawn by the Examiner in the Office action mailed 29 December 2005.

Reasons for allowance

The following is an examiner's statement of reasons for allowance. A new search was conducted with respect to the amendment submitted on 8 January 2007. Sohlström et al. (Growth Hormone & IGF Research 2001, 11; 392-398) teach the administration of IGF-II on day 20 of pregnancy in guinea pigs (i.e., during the first half of pregnancy), via subcutaneous injection. Applicants were awarded a U.S. filing date of 30 August 2002, in which priority is claimed to Australian application PR7331, filed 30 August 2001. A certified copy of the Australian application PR7331 was provided, and at p. 9, lines 17-19, for example, it states that IGF-II should be used in early pregnancy, thus clearly shows that it was appreciated by Applicants' that IGF-II must be administered early pregnancy on 30 August 2001. Sohlström et al. was published before 30 August 2002, but after 30 August 2001, thus this reference does not anticipate the claimed invention under 35 U.S.C. 102(a).

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably

Application/Control Number: 10/789,105

Art Unit: 1649

accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Claims 1-5 and 7 are allowed. In response to the restriction requirement mailed 5 October 2005, Applicants did not distinctly and specifically point out the supposed errors in the restriction requirement, thus the election was treated as an election without traverse (MPEP § 818.03(a)), and claims 8-17 are hereby cancelled.

Art Unit: 1649

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christina Borgeest whose telephone number is 571-272-4482. The examiner can normally be reached on 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, Ph.D. can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Christina Borgeest, Ph.D.

ELIZABETH KEMMERER PRIMARY EXAMINER

Chjabett C. Temmens